Home

Larry G. Edwards

CIK 1733062 · Chief Executive Officer · last filed 2022-08-24

Larry G. Edwards is a Chief Executive Officer who has filed 32 SEC Form 4 insider transactions across 2 companies since 2018. 29 SEC filings were submitted jointly with PHARMACEUTICAL CO LA JOLLA.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

32

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O TETRAPHASE PHARMACEUTICALS, INC.
480 ARSENAL STREET, SUITE 110
WATERTOWN, MA 02472
Related Filers
PHARMACEUTICAL CO LA JOLLA — 29 joint filings, latest 2022-08-24
Innoviva, Inc. — 1 joint filings, latest 2022-08-26
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Chief Executive Officer 11,969 $6.22 $74.4K $0 27 2022-04-18
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted See Remarks 0 — — $0 4 2020-07-29

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-08-24 — Disp (D) −11,969 -$74.6K
2022-04-18 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +296 $1.1K EDGAR
2022-04-04 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +334 $1.2K EDGAR
2022-03-17 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +361 $1.2K EDGAR
2022-03-02 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +350 $1.2K EDGAR
2022-02-17 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +320 $1.2K EDGAR
2022-02-02 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +4,170 $16.4K EDGAR
2022-01-19 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +273 $1.1K EDGAR
2022-01-14 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) — $0 EDGAR
2022-01-04 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +233 $913 EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.